<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03410277</url>
  </required_header>
  <id_info>
    <org_study_id>MED-2017-26317</org_study_id>
    <nct_id>NCT03410277</nct_id>
  </id_info>
  <brief_title>Recurrent Hypoglycemia in Type 1 Diabetes (Aim 1)</brief_title>
  <official_title>Measurement of Glucose Homeostasis in Human Brain by NMR: Effect of Recurrent Hypoglycemia on Type 1 Diabetes (Aim 1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Minnesota</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will explore the cerebral mechanisms of impaired awareness of hypoglycemia (IAH)&#xD;
      in type 1 diabetics following exposure to experimental recurrent hypoglycemia (HG). To induce&#xD;
      IAH, patients with T1D identified to have normal awareness of hypoglycemia (NAH) will undergo&#xD;
      three 2-hour long hypoglycemic clamps. Neurochemical profiles will be measured by high field&#xD;
      MRS before and after induction of IAH. Subject glycemic variability for 2 weeks and&#xD;
      activity/sleep for 1 week before each study will be monitored as all factors have been shown&#xD;
      to alter responses to HG.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The long-term goal of this project is to identify how recurrent hypoglycemia (HG) leads to&#xD;
      the clinical syndrome of impaired awareness of hypoglycemia (IAH) in type 1 diabetes (T1D).&#xD;
      This study will test the hypothesis that recurrent HG in T1D leads to an upregulation in&#xD;
      brain glucose transport and alterations in glutamatergic and GABAergic tone. The&#xD;
      investigators will use MRS methodology that permits evaluation of cerebral cortex and&#xD;
      hypothalamus in the same session to simultaneously evaluate the cerebral correlates/mediators&#xD;
      of impaired awareness and impaired counterregulatory hormone responses (CRR). High MR data&#xD;
      quality and reproducibility will be ensured by using high field MR scanners and technical&#xD;
      advances (automated voxel placement, real-time voxel position, frequency, shim updates).&#xD;
      Continuous glucose monitoring and actigraphy will be used to chronicle glucose variability&#xD;
      and activity/exercise/sleep in the weeks before each experiment to assess the impact of these&#xD;
      variables on IAH.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 24, 2018</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neurochemical response to HG before and after induction of IAH</measure>
    <time_frame>240 Minutes</time_frame>
    <description>The difference in neurochemical response (GABA, glutamate, and glucose) to HG during the first clamp study compared to the neurochemical response to HG after the induction of IAH as determined by the last clamp.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antecedent glycemia concentration</measure>
    <time_frame>16 days</time_frame>
    <description>The difference in antecedent glycemia concentration associated with the differences seen in the primary outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antecedent physical activity</measure>
    <time_frame>16 days</time_frame>
    <description>The difference in antecedent physical activity associated with the differences seen in the primary outcome.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>All Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental hypoglycemia</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Experimental hypoglycemia</intervention_name>
    <description>Experimental hypoglycemia with and without MRI</description>
    <arm_group_label>All Subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type 1 diabetes diagnosed on clinical or laboratory grounds&#xD;
&#xD;
          -  Diabetes duration 2 - 30 years&#xD;
&#xD;
          -  Hemoglobin A1C &lt;8.5%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Impaired awareness of hypoglycemia as determined by the Cox and Gold questionnaires&#xD;
&#xD;
          -  Pregnant or plan to become pregnant during the study period&#xD;
&#xD;
          -  Uncontrolled hypertension (blood pressure &gt; 145/95 mmHg at screening)&#xD;
&#xD;
          -  Evidence of autonomic neuropathy (presence of orthostatic hypotension or history of&#xD;
             gastroparesis)&#xD;
&#xD;
          -  Proliferative retinopathy&#xD;
&#xD;
          -  Impaired kidney function (GFR &lt; 45)&#xD;
&#xD;
          -  History of myocardial infarction, stroke, seizures, neurosurgical procedures, major&#xD;
             depression requiring hospitalization within the last 5 years, arrhythmias&#xD;
&#xD;
          -  Current substance abuse&#xD;
&#xD;
          -  Use of drugs that can alter glucose metabolism including but not limited to&#xD;
             glucocorticoids and niacin, and excluding insulin and glucose lowering drugs used to&#xD;
             treat diabetes, as determined by a clinician&#xD;
&#xD;
          -  Inability to undergo MRI scanning, including but not limited to unable to remain still&#xD;
             in an MRI scanner for more than 30 minutes, claustrophobia, presence of paramagnetic&#xD;
             substances or pacemakers in body, weight over 300 lbs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth R Seaquist, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anjali Kumar, PA-C</last_name>
    <phone>612-301-7040</phone>
    <email>studydiabetes@umn.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth R Seaquist, MD</last_name>
      <phone>612-624-9176</phone>
      <email>studydiabetes@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Elizabeth R Seaquist, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gulin Oz, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 18, 2018</study_first_submitted>
  <study_first_submitted_qc>January 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 25, 2018</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

